Is Low Dietary Intake of Omega-3 Fatty Acids Associated With Depression?

Reeta Hakkarainen, M.B.
Timo Partonen, M.D.
Jari Haukka, Ph.D.
Jarmo Virtamo, M.D.
Demetrius Albanes, M.D.
Jouko Lönnqvist, M.D., Ph.D.

Objective: This study examined the association between the dietary intake of omega-3 fatty acids and low mood, major depression, and suicide.

Method: A total of 29,133 men ages 50 to 69 years participated in a population-based trial in Finland. The intake of fatty acids and fish consumption were calculated from a diet history questionnaire. Self-reported depressed mood was recorded three times annually, data on hospital treatments due to a major depressive disorder were derived from the National Hospital Discharge Register, and suicides were identified from death certificates.

Results: There were no associations between the dietary intake of omega-3 fatty acids or fish consumption and depressed mood, major depressive episodes, or suicide.

Conclusions: Dietary intake of omega-3 fatty acids showed no association with low mood level.

Omega-3 fatty acids are essential long-chain polyunsaturated fatty acids that are concentrated in the CNS, retina, and testes in humans. Alpha-linolenic acid is present in plants and is needed for the synthesis of eicosapentaenoic and docosahexaenoic acids that are received directly from marine sources.

There is some evidence that omega-3 fatty acids are linked to depression (1). Studies have reported reduced levels of omega-3 fatty acids in plasma and cell membranes from depressed patients (2–4). One double-blind, placebo-controlled trial (5) has shown that omega-3 supplements improve the short-term clinical course of patients with bipolar disorder.

Our aim was to study the association between the dietary intake of omega-3 fatty acids and low mood, depression, and suicide. Consumption of fish rich in long-chain omega-3 fatty acids, specifically, was assessed.

Method

This study was based on a cohort (N=29,133) from a randomized, double-blind, placebo-controlled primary prevention trial—the ATBC study (6). The study participants were recruited from the total male population of 50 to 69 years of age that was residing in southwestern Finland in 1985 (N=290,406). The review boards of the participating institutions approved the study. All subjects gave written informed consent before random assignment.

Diet and alcohol consumption were assessed through a validated food-use questionnaire to measure the habitual dietary intake over the previous year. The reproducibility of this method was 0.6 to 0.7, and the validity was 0.6 to 0.7 for most nutrients (7). The dietary intake of omega-3 fatty acids at baseline was calculated. The study endpoints were self-reported depressed mood, hospital treatment for a major depressive disorder, and death from suicide. The subjects reported feelings of anxiety and depression experienced in the 4 months since their previous study visit (three times annually) during the trial, ranging from 5 to 8 years in duration (median=6). Data on hospital treatment due to depressive disorder were derived from the National Hospital Discharge Register, which covers inpatient admissions to all medical and psychiatric hospitals in Finland. The follow-up of survival extended to Dec. 31, 1994. Data regarding deaths were derived from the Central Population Register, and the cause of death was reviewed from death certificates. Details of the assessment have been described elsewhere (8).

Both placebo and intervention groups were included in the analysis. Cox’s proportional hazards regression models were used to estimate the relationships between baseline dietary intake of omega-3 fatty acids, categorized in tertiles, and the first measures of low mood level. Potential risk factors for both major depressive disorder and suicide (age, body mass index, energy intake, serum total cholesterol level, high-density lipoprotein cholesterol level, consumption of alcohol, education, marriage, self-reported depression, self-reported anxiety, and smoking) were entered into the models as covariates. Dietary factors were adjusted for energy intake in the models (9). A test for trend was calculated.

Results

There was no significant association of fish consumption or intake of omega-3 fatty acids with any of the study endpoints (Table 1). A small, marginally elevated risk of self-reported depression was suggested in the highest tertile of fish consumption compared to the lowest tertile. A trend test showed the significance of fish consumption for self-reported depressed mood (z=2.09, df=1, p<0.04).

Discussion

Dietary intake of omega-3 fatty acids showed no association to low mood level and related outcomes. We linked the dietary intake of omega-3 fatty acids to the...
three-level assessment of low mood, as a symptom (self-report), and as pathology (disorder or suicide) in a population. A validated method to quantitative long-term diet was used. Even so, the present findings may not be generalized beyond our study population or to older male smokers.

Our findings conflict with the results of a controlled trial that suggested that fish omega-3 fatty acids might improve the short-term course of bipolar disorder (5). The dose of omega-3 fatty acids in that trial (9.6 g/day), however, exceeded the dietary intake level of our study (total intake of 2.2 g/day or 0.47 g/day from fish).

The average intake of omega-3 fatty acids tends to be rather similar in most of the Western countries. For example, the average intake of omega-3 fatty acids was 1.2 g/day in the United States (10). Therefore, the overall amount of omega-3 fatty acids in the diet of our population (2.2 g/day) is higher but still in line with that of other industrialized populations.

In addition, we compared the intake of omega-3 fatty acids of the highest decile and the lowest decile with that of the middle tertile. It is unlikely that there is a ceiling effect, since the intake does vary between the individuals and was rather low in those of the lowest decile. Whether omega-3 fatty acids raise mood and whether the necessary intake can be received from a certain diet are important questions that must await further studies.

Table 1. Baseline Dietary Intake of Omega-3 Fatty Acids and Fish, in Tertiles, in Relation to Risk for Self-Reported Depressed Mood and Hospital Treatment Due to Major Depression in the Following 9 Years

<table>
<thead>
<tr>
<th>Dietary Item and Tertile</th>
<th>Self-Reported Depressed Mood</th>
<th>Hospital Treatment Due to Major Depression</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline Intake (g/day)</td>
<td>Baseline Intake (g/day)</td>
</tr>
<tr>
<td></td>
<td>Subjects Without Depressed Mood (N=18,499)</td>
<td>Subjects With Depressed Mood (N=8,612)</td>
</tr>
<tr>
<td></td>
<td>Mean</td>
<td>SD</td>
</tr>
<tr>
<td>Fish</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;sup&gt;1b&lt;/sup&gt;</td>
<td>39.35</td>
<td>29.81</td>
</tr>
<tr>
<td>2</td>
<td>1.04</td>
<td>0.98–1.09</td>
</tr>
<tr>
<td>3</td>
<td>1.06</td>
<td>1.00–1.12</td>
</tr>
<tr>
<td>Omega-3 fatty acids</td>
<td></td>
<td></td>
</tr>
<tr>
<td>from fish</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;sup&gt;1b&lt;/sup&gt;</td>
<td>0.46</td>
<td>0.28</td>
</tr>
<tr>
<td>2</td>
<td>1.03</td>
<td>0.98–1.09</td>
</tr>
<tr>
<td>3</td>
<td>1.03</td>
<td>0.97–1.08</td>
</tr>
<tr>
<td>Omega-3 fatty acids</td>
<td></td>
<td></td>
</tr>
<tr>
<td>from vegetables</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;sup&gt;1b&lt;/sup&gt;</td>
<td>1.70</td>
<td>0.77</td>
</tr>
<tr>
<td>2</td>
<td>1.03</td>
<td>0.98–1.09</td>
</tr>
<tr>
<td>3</td>
<td>1.02</td>
<td>0.97–1.08</td>
</tr>
<tr>
<td>Total omega-3 fatty</td>
<td></td>
<td></td>
</tr>
<tr>
<td>acids</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;sup&gt;1b&lt;/sup&gt;</td>
<td>2.14</td>
<td>0.88</td>
</tr>
<tr>
<td>2</td>
<td>1.02</td>
<td>0.97–1.08</td>
</tr>
<tr>
<td>3</td>
<td>1.02</td>
<td>0.97–1.08</td>
</tr>
</tbody>
</table>

<sup>a</sup>The relative risks were adjusted for the baseline age, body mass index, energy intake, serum total and high-density lipoprotein cholesterol levels, consumption of alcohol, education, marriage, self-reported anxiety, self-reported depression, and smoking.

<sup>b</sup>Reference category.

Received Nov. 28, 2002; revisions received June 3 and Aug. 5, 2003; accepted August 23, 2003.

References

Association Between Allelic Variation of Serotonin Transporter Function and Neuroticism in Anxious Cluster C Personality Disorders

Christian P. Jacob, M.D.
A. Strobel, Ph.D.
K. Hohenberger, M.D.
T. Ringel, M.D.
L. Gutknecht, Ph.D.
A. Reif, M.D.
B. Brocke, Ph.D.
K.P. Lesch, M.D.

Objective: Association between the low-activity variant of a polymorphism in the transcriptional control region of the serotonin transporter (5-HTTLPR) and neuroticism or harm avoidance was found in several but not all studies. The authors analyzed the influence of 5-HTTLPR variants on personality disorders.

Method: Patients with personality disorders (N=320) and healthy volunteers (N=281) were studied with the Revised NEO Personality Inventory and the Tridimensional Personality Questionnaire. All were genotyped for 5-HTTLPR variants.

Results: No differences in 5-HTTLPR genotype distribution were detected between patients with cluster B and C personality disorders and comparison subjects. In contrast, among patients with a cluster C diagnosis, carriers of the low-activity short allele of the 5-HTTLPR exhibited higher neuroticism scores than noncarriers.

Conclusions: These findings support the notion that there is no general association between the 5-HTTLPR and anxiety-related traits and that differential gene effects and/or gene-by-environment interactions are likely operative in distinct clinical subpopulations.

The human serotonin (5-HT) transporter (5-HTT), a critical regulator of serotonergic function and the initial target of antidepressant drugs, is encoded by a single-copy gene (SLC6A4) located on chromosome 17q12. 5-HTT gene transcription is modulated by a 44-bp length variation in its upstream regulatory region, termed short versus long 5-HTTLPR (1). Studies of allelic promoter activity in immortalized raphe cells (2), mRNA concentrations in the raphe complex of the human postmortem brain (3), platelet 5-HT uptake and content (4), 5-HT system responsivity elicited by pharmacological challenge tests with clomipramine and fenfluramine (5, 6), mood changes following tryptophan depletion (7), and single photon emission computed tomography of human brain 5-HTT (8) have confirmed that the 5-HTTLPR short variant restricts 5-HTT availability and ultimately 5-HTT reuptake.

Allelic variation in 5-HTT function was found to account for approximately 8% of the inherited variance in anxiety- and depression-related personality traits in individuals as well as in sibships (1). In addition to studies of the low-activity short variant’s effect on personality traits, a role for 5-HTTLPR has been suggested in a variety of psychiatric diseases, including major depression and bipolar disorders (9, 10). Individuals with one or two copies of the low-activity short allele of 5-HTTLPR (long-short and short-short) exhibit greater neuronal activity of the amygdala in response to fearful stimuli when compared with individuals homozygous for the long allele, as assessed by blood-oxygen-level-dependent functional magnetic resonance imaging (11). Furthermore, the rates of major depression were found to be strongly influenced by the number of stressful life events in carriers of short alleles of the 5-HTTLPR but not in the individuals with the long-long genotype (12).

In a population- and family-based design, association between the 5-HTTLPR short allele and higher scores for neuroticism and harm avoidance was initially shown in a predominantly male group (1) and, subsequently, in an in-


5-HTTLPR variants.